



|                                       |                                                                                                                                                                                     |                 |                |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|----------------|
| <b>Curriculum Vitae Europass</b>      |                                                                                                                                                                                     |                 |                |
| <b>PERSONAL INFORMATION</b>           |                                                                                                                                                                                     |                 |                |
|                                       | Francesca Matilde Schipilliti<br>License Number "Ordine Provinciale di Roma dei Medici Chirurghi e degli Odontoiatri"                                                               |                 |                |
| <b>WORK EXPERIENCE</b>                |                                                                                                                                                                                     |                 |                |
| <b>Present</b>                        | Medical Doctor<br><br>ASL RM5, S. Giovanni Evangelista, Tivoli                                                                                                                      |                 |                |
| <b>EDUCATION AND TRAINING</b>         |                                                                                                                                                                                     |                 |                |
| 2020- 2023                            | Specialization in Medical Oncology<br>Medical Oncology Unit, Sant'Andrea Hospital, 1035-1039, Grottarossa Street, 00189, Rome, Italy - University of Rome "Sapienza" – 60/60 e lode |                 |                |
| 2018-2020                             | Specialist training in Medical Oncology<br><b>Medical Oncology Unit, COM, Modena Hospital, via del Pozzo 71, Modena, Italy, UNIMORE University</b>                                  |                 |                |
| 2012-2018                             | Degree in Medicine and Surgery<br>Faculty of Medicine and Psychology - University of Rome "Sapienza" 110/110 e lode                                                                 |                 |                |
| 2008-2012                             | High School Diploma (Classic Diploma)<br>Classic High School "Orazio", Rome<br>100/100                                                                                              |                 |                |
| <b>PERSONAL SKILLS</b>                |                                                                                                                                                                                     |                 |                |
| Mother Tongue                         | <b>Italian</b>                                                                                                                                                                      |                 |                |
| Other Languages                       | <b>English</b>                                                                                                                                                                      |                 |                |
|                                       | <b>Reading/Understanding</b>                                                                                                                                                        | <b>Speaking</b> | <b>Writing</b> |
|                                       | Good                                                                                                                                                                                | Good            | Good           |
| <b>INVOLVEMENT IN CLINICAL TRIALS</b> | Sub-Investigator in sponsored/non sponsored clinical trials                                                                                                                         |                 |                |

## PUBLICATIONS

[https://pubmed.ncbi.nlm.nih.gov/?term=schipilliti&filter=date&search.y\\_5](https://pubmed.ncbi.nlm.nih.gov/?term=schipilliti&filter=date&search.y_5)

- Gadaleta-Caldarola G, Lanotte L, Infusino S, Gadaleta-Caldarola A, Schipilliti FM, Citrigno C, Petrarota C, Cusmai A, Rizzo A. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. *Cancer Treat Res Commun.* 2023;37:100775. doi: 10.1016/j.ctarc.2023.100775. Epub 2023 Nov 8. PMID: 37956525.
- Rizzo A, Schipilliti FM, Di Costanzo F, Acquafredda S, Arpino G, Puglisi F, Del Mastro L, Montemurro F, De Laurentiis M, Giuliano M. Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis. *ESMO Open.* 2023 Dec;8(6):102198. doi: 10.1016/j.esmoop.2023.102198. Epub 2023 Dec 14. PMID: 38100933; PMCID: PMC10774952.
- Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. **The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review.** *Pharmaceuticals (Basel).* 2021 Jan 8;14(1):43. doi: 10.3390/ph14010043. PMID: 33429973; PMCID: PMC7827379
- Roberto M, Carconi C, Cerreti M, Schipilliti FM, Botticelli A, Mazzuca F, Marchetti P. **The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?** *Front Immunol.* 2021 Aug 20;12:704942. doi: 10.3389/fimmu.2021.704942. PMID: 34489956; PMCID: PMC8417795.
- Bertolini F, Trudu L, Banchelli F, Schipilliti F, Napolitano M, Alberici MP, Depenni R, D'Angelo E, Mattioli F, Rubino L, Presutti L. **Second primary tumors in head and neck cancer patients: The importance of a "tailored" surveillance.** *Oral Dis.* 2021 Sep;27(6):1412-1420. doi: 10.1111/odi.13681. Epub 2020 Nov 8. PMID: 33051941.
- Napolitano M, Schipilliti FM, Trudu L, Bertolini F. **Immunotherapy in head and neck cancer: The great challenge of patient selection.** *Crit Rev Oncol Hematol.* 2019 Dec;144:102829. doi: 10.1016/j.critrevonc.2019.102829. Epub 2019 Nov 3. PMID: 31739116.
- Schipilliti FM, Onorato M, Arrivi G, Panebianco M, Lerinò D, Milano A, Roberto M, Capalbo C, Mazzuca F. **Electrochemotherapy for solid tumors: literature review and presentation of a novel endoscopic approach.** *Radiol Oncol.* 2022 Aug 14;56(3):285-291. doi: 10.2478/raon-2022-0022. PMID: 35776844.
- Mazzuca F, Roberto M, Arrivi G, Sarfati E, Schipilliti FM, Crimini E, Botticelli A, Di Girolamo M, Muscaritoli M, Marchetti P. **Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study.** *Integr Cancer Ther.* 2019 Jan-Dec;18:1534735419866920. doi: 10.1177/1534735419866920. PMID: 31370717; PMCID: PMC6681246.
- Crimini E, Roberto M, Degli Effetti V, Marchetti P, Botticelli A, Schipilliti FM, Arrivi G, Mazzuca F. **Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient.** *Case Rep Oncol Med.* 2019 Mar 28;2019:2507642. doi: 10.1155/2019/2507642. PMID: 31049235; PMCID: PMC6458881.
- Bonucci M, Marino Francesco V. **Principi di oncologia integrata, Tecniche Nuove Editore, Elettrochemioterapia**, pp 74-76, cap.3 Mazzuca F, Schipilliti FM, Arrivi G.
- Alessia, S., Matilde, S.F., Chrystel, I. *et al.* The quality of palliative sedation in end-stage disease: audit from a department of oncology and haematology. *Support Care Cancer* **30**, 3849–3855 (2022). <https://doi.org/10.1007/s00520-021-06730-8>
- Gadaleta-Caldarola G, Lanotte L, Infusino S, Gadaleta-Caldarola A, Schipilliti FM, Citrigno C, Petrarota C, Cusmai A, Rizzo A. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. *Cancer Treat Res Commun.* 2023;37:100775. doi: 10.1016/j.ctarc.2023.100775. Epub 2023 Nov 8. PMID: 37956525.

|              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PUBLICATIONS | <p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=schipilliti&amp;filter=datesearch.y_5">https://pubmed.ncbi.nlm.nih.gov/?term=schipilliti&amp;filter=datesearch.y_5</a></p> <ul style="list-style-type: none"> <li>- Schipilliti FM, Drittone D, Mazzuca F, La Forgia D, Guven DC, Rizzo A. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer. Heliyon. 2024 Mar 22;10(7):e28385. doi: 10.1016/j.heliyon.2024.e28385. PMID: 38560142; PMCID: PMC10981107.</li> <li>- Drittone D, Schipilliti FM, Arrivi G, Mazzuca F. Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy applications in upper and lower gastrointestinal cancer, a review. Oncol Rev. 2024 Nov 26;18:1496141. doi: 10.3389/or.2024.1496141. PMID: 39659741; PMCID: PMC11628282.</li> <li>- Rizzo A, Schipilliti FM, Di Costanzo F, Acquafredda S, Arpino G, Puglisi F, Del Mastro L, Montemurro F, De Laurentiis M, Giuliano M. Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis. ESMO Open. 2023 Dec;8(6):102198. doi: 10.1016/j.esmoop.2023.102198. Epub 2023 Dec 14. PMID: 38100933; PMCID: PMC10774952.</li> </ul> |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

In compliance with the UE GDPR 2016/679 and the Italian Legislative Decree n.196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.

Firma | .....Dott.ssa Francesca Matilde Schipilliti.....

Data: 15.07.2025